History
Glycotope was founded in February 2001 by Dr. Steffen Goletz, CSO of Nemod Biotherapeutics and former head of a research group at the Max-Delbrueck-Centre for Molecular Medicine in Berlin, and Dr. Andreas Eckert, CEO and founder of Eckert & Ziegler Strahlen- und Medizintechnik AG.
Starting with eight employees to develop the GlycoExpress™ technology, today the company employs more than 150 people at two sites in Berlin and Heidelberg and by applying the GlycoExpress™ technology significantly widend its focus from a pure technology provider to the development of proprietary and strongly improved 2nd generation biotherapeutics. Part of this process was the acquisition of all assets of the Nemod Biotherapeutics Co. KG in 2007.
GLYCOTOPE BIOTECHNOLOGY, located in Heidelberg, comprises the former biotechnological activities of Orpegen Pharma, which Glycotope acquired in 2008. Glycotope Biotechnology allows Glycotope to produce its glycooptimized biotherapeutics under GMP conditions.
Based on Glycotope’s technology portfolio and business concepts, the participation of Hexal founders Thomas & Andreas Struengmann in 2007 constituted one of the largest biotech investments in Germany.
Glycotope is located in Berlin at the place of its foundation on the Biotech-Campus Buch in the Northeast of Berlin.
| 2011 |
Glycotope initiates Phase I for TrasGEX™ / GT-MAB 7.3-GEX, a glycooptimized version of TrastuzuMab / Herceptin™. With the follicle-stimulating hormone FSH-GEX™ / GT-GP 2.4-GEX Glycotope’s first glycooptimized non-antibody product enters the clinic. |
| 2010 | Glycotope´s first BioBetter product CetuGEX™ / GT-MAB 5.2-GEX an improved CetuxiMab / Erbitux™ starts clinical trials. |
| 2009 | Glycotope´s lead antibody PankoMab-GEX™ / GT-MAB 2.5-GEX enters clinical phase I. Simultaneously, also GlycoExpress receives regulatory approval. |
| 2008 | Acquisition of most Orpegen Pharma assets and formation of Glycotope-Biotechnology as GMP-production unit of Glycotope |
| 2007 | One of the largest series A financing rounds in Europeen biotech history wins T. + A. Strüngmann as investors |
| 2001 | Foundation of Glycotope in Berlin |
| 2011 |
Expansion of DSP-capacities for production of up to 4 kg recombinant antibodies per year |
| 2010 | Initial operation of 2 x 300 L perfusion reactors having a batch volume of up to 9,000 L each |
| 2009 |
Approval for „Fill and Finish“ of clinical grade material |
| 2008 | GLYCOTOPE acquires most assets of ORPEGEN Pharma and incorporates GLYCOTOPE Biotechnology |
| 2004 | Inauguration of a new multi-purpose biotechnology facility |
| 1999 | GMP production of monoclonal antibodies |
| 1989 | Contract development and production Erythropoietin (rhEPO) for clinical trials up to phase III |
| 1982 | Foundation of ORPEGEN in Heidelberg |
